OptimizeRx downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded OptimizeRx (OPRX) to Sector Perform from Outperform with a price target of $6, down from $7. The firm believes OptimizeRx remains well positioned to benefit over the longer term as an increasing proportion of pharma sales and marketing budgets shift into digital channels. However, in the nearer term, RBC sees the ongoing transition taking place in its direct-to-consumer business acting as a “meaningful headwind” to revenue growth in 2025. It also believes the stock and its valuation will remain range-bound until growth in its legacy provider business becomes more evident.